2024-519813-74-00
Not yet recruiting
Phase 1
A phase 1, double-blind, placebo-controlled, randomized, single ascending dose and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of GHF-201 in healthy adult volunteers
CCDRD Cooperative Clinical Drug Research and Development AG, GHF-Golden Heart Flower Ltd.2 sites in 1 country32 target enrollmentStarted: April 17, 2025Last updated:
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- CCDRD Cooperative Clinical Drug Research and Development AG, GHF-Golden Heart Flower Ltd.
- Enrollment
- 32
- Locations
- 2
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Head of Product Development: Yossi Gilgun-Sherki
Scientific
GHF-Golden Heart Flower Ltd.
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy Participants2025-521914-25-00Clexio Biosciences Ltd.110
Recruiting
Phase 1
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.2024-512722-28-00Bioprojet Pharma161
Recruiting
Phase 1
Double-blind, randomized, placebo-controlled pilot clinical trial to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2 macrophages and fat-derived mesenchymal cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV)2023-507700-32-00Peaches Biotech S.L.50
Completed
Phase 1
A three part randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and preliminary efficacy of an inhaled (nebulized) phage cocktail in healthy subjects and in patients with chronic colonization of the lung with Pseudomonas aeruginosa2023-507203-55-00Charite Research Organisation GmbH50
Not yet recruiting
Phase 1
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus2025-522551-25-00AstraZeneca AB28